Cholinergic Adverse Effects of Cholinesterase Inhibitors in Alzheimer??s Disease
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 18 (11) , 853-862
- https://doi.org/10.2165/00002512-200118110-00006
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Cholinesterase Inhibitors for the Treatment of Alzheimer??s Disease in the ElderlyDrugs & Aging, 2000
- Acetylcholinesterase inhibitors in the treatment of Alzheimer’s diseaseExpert Opinion on Investigational Drugs, 1999
- The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1Dementia and Geriatric Cognitive Disorders, 1999
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsawBMJ, 1999
- Metrifonate treatment of the cognitive deficits of Alzheimer's diseaseNeurology, 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Effects of Central Muscarinic-1 Receptor Stimulation on Blood Pressure RegulationHypertension, 1997
- The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled TrialDementia and Geriatric Cognitive Disorders, 1996
- “Mini-mental state”Journal of Psychiatric Research, 1975